Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 14, 2020

SELL
$1.8 - $3.05 $368,398 - $624,231
-204,666 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$0.71 - $4.91 $145,312 - $1 Million
204,666 New
204,666 $917,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $389M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Cvi Holdings, LLC Portfolio

Follow Cvi Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cvi Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cvi Holdings, LLC with notifications on news.